Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 228,400 shares, an increase of 121.3% from the September 30th total of 103,200 shares. Approximately 5.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,720,000 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC bought a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.38% of Alzamend Neuro at the end of the most recent quarter. 49.61% of the stock is owned by institutional investors and hedge funds.
Alzamend Neuro Price Performance
NASDAQ:ALZN traded down $0.01 during trading hours on Friday, reaching $1.61. 94,250 shares of the company traded hands, compared to its average volume of 545,744. Alzamend Neuro has a 1-year low of $1.40 and a 1-year high of $30.00. The firm’s 50-day moving average is $2.10 and its 200-day moving average is $4.00. The stock has a market cap of $12.85 million, a P/E ratio of -1.63 and a beta of -0.03.
Alzamend Neuro Company Profile
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Further Reading
- Five stocks we like better than Alzamend Neuro
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Retail Stocks Investing, Explained
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.